Today: 19 June 2026
Why Procter & Gamble stock is holding up as Wall Street dips ahead of earnings
13 January 2026
1 min read

Why Procter & Gamble stock is holding up as Wall Street dips ahead of earnings

New York, January 13, 2026, 13:37 EST — Regular session

  • Procter & Gamble shares edged up roughly 0.1% in afternoon trading, defying the drop seen in major index ETFs.
  • The stock gained 1.1% Monday, trading on volume above its average, pushing its winning streak a bit longer.
  • All eyes are on the Jan. 22 earnings webcast — marking CEO Shailesh Jejurikar’s first quarterly call.

Procter & Gamble (PG.N) shares edged up 0.1% to $143.59 on Tuesday, staying positive as the wider market slipped. S&P 500, Dow, and Nasdaq ETFs fell between 0.3% and 0.7% in afternoon trading.

Investors are shifting away from expensive growth stocks, turning to “overlooked” sectors like consumer staples, Reuters noted, even as major indexes fell. Ryan Detrick, chief market strategist at Carson Group, emphasized, “the lifeblood of a bull market is rotation.” Reuters

The move followed a Labor Department report revealing U.S. consumer prices climbed 0.3% in December, marking a 2.7% increase from a year ago. Core CPI, excluding food and energy, held steady at 2.6% year-over-year, fueling ongoing debate over potential rate cuts despite expectations the Fed will keep rates steady later this month.

P&G closed up 1.12% on Monday at $143.46, marking its third straight daily gain. Trading volume reached 12.5 million shares, surpassing the 50-day average of roughly 10 million. The stock remains about 20% below its 52-week high.

The upcoming major event is the company’s fiscal second-quarter earnings call, set for Jan. 22 at 8:30 a.m. ET, per its investor relations calendar.

This marks the first quarterly call since Shailesh Jejurikar stepped in as president and CEO on Jan. 1, following his election by the board last year, according to a filing.

When it comes to P&G, investors zero in on a handful of key factors: the split between sales growth driven by pricing versus unit volume, signs of shoppers trading down, and management’s outlook on costs heading into spring.

Still, the margin for error shrinks if costs don’t ease and promotional activity ramps up. Zacks Investment Research noted Tuesday that tariff-related expenses continue to pose a “meaningful headwind,” with about $500 million in higher pre-tax costs baked into P&G’s outlook. The firm also pointed to a cooling consumer environment. Finviz

Peers are right next door. Colgate-Palmolive (CL.N) and Church & Dwight (CHD.N) wrestle with the same pricing-versus-volume dilemma, and if consumers push back, the impact won’t be limited to just one category.

Traders have their eyes on one date: Jan. 22, when P&G releases its results. The key will be management’s take on pricing, volumes, and costs.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • JPMorgan European Discovery Trust Declares Final Dividend for 2026
    June 19, 2026, 3:16 AM EDT. JPMorgan European Discovery Trust plc announced a final dividend of 13.0 pence per share, pending shareholder approval at the upcoming Annual General Meeting. The dividend will be paid on August 3, 2026, to shareholders on record as of July 3, 2026, with an ex-dividend date of July 2, 2026. A dividend reinvestment plan is available, with the last election date set for July 13, 2026. The announcement was made by JPMorgan Funds Limited, the company's secretary, reflecting the trust's commitment to returning value to shareholders.

Latest articles

Kardigan pops in first Nasdaq trading after $400 million IPO

Kardigan pops in first Nasdaq trading after $400 million IPO

19 June 2026
Kardigan surged 37.5% above its $16 IPO price to close at $22 after raising $400 million in an upsized Nasdaq debut, signaling renewed investor appetite for large biotech IPOs as the company advances three late-stage cardiovascular drug candidates.
Roblox stock jumps as BMO flags a breakout game and Feb. 5 earnings loom (RBLX)
Previous Story

Roblox stock jumps as BMO flags a breakout game and Feb. 5 earnings loom (RBLX)

Penumbra (PEN) stock slides 5% after CEO flags manufacturing shift at JPM conference
Next Story

Penumbra (PEN) stock slides 5% after CEO flags manufacturing shift at JPM conference

Go toTop